HIMS

$22.02-2.14 (-8.86%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Hims & Hers Health, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$22.02
Potential Downside
41.7%
Whystock Fair Value$12.83
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-pre...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
43.18
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
35.79%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.70

Recent News

Insider Monkey
Mar 21, 2026

Hims & Hers (HIMS) Tumbles 8.86% on Market Bloodbath, Profit-Taking

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stock Market Casualties You Can’t Ignore Today. Hims & Hers fell by 8.86 percent on Friday to close at $22.02 apiece, as investors unloaded positions amid a combination of market pessimism and profit-taking, having soared by as much as 88 percent already this month. […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 21, 2026

Does Hims & Hers (HIMS) Novo Nordisk Deal Quietly Redraw Its Risk Reward Profile?

Earlier in March 2026, Novo Nordisk agreed to resume selling its weight-loss drugs through the Hims & Hers Health platform, ending a public legal conflict over copycat medications and restoring a commercial relationship in one of healthcare’s most competitive categories. Days later, Hims & Hers appointed veteran communicator Kathryn Beiser as Chief Communications Officer, underscoring the company’s focus on strengthening its brand and explaining its broader telehealth ambitions to...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 20, 2026

Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance

The modeled fair value for Hims & Hers Health has been revised from about US$44.36 to around US$23.69, a reset of roughly 47% in the price target framework. This shift aligns with Street commentary that balances enthusiasm around the renewed Novo Nordisk GLP-1 agreement with concerns related to recent results, 2026 guidance, legal and regulatory risk, and execution on new offerings. As you read on, you will see how these factors shape the evolving analyst narrative and what to watch...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 19, 2026

1 Growth Stock with All-Star Potential and 2 That Underwhelm

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 18, 2026

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.15, indicating a -7.33% shift from the previous trading day.

BEARISH
Negative press. News cycle fixated on risk factors or misses.